Under the agreement, products would be developed and submitted for approval to the USFDA. Ranbaxy Pharmaceuticals Inc would market the products under the company's label.
Zonisamide Capsules, which are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy, have total annualised sales of $170.30 million, Ranbaxy informed the Stock Exchanges.
"Such partnerships with companies like Invagen, who have capabilities and competencies to develop bioequivalent generic product for the marketplace, are naturally beneficial to both organisations while having a positive economic impact on the US healthcare system," Atul Malhotra, president, Ranbaxy Inc said.